Skip to main content

Experimental Haematology Laboratory (HEMEXP)

The Experimental Haematology Laboratory is dedicated to fundamental and applied research in the field of haematology and immunology. It operates in symbiosis with the Institut Bordet Haematology Clinic. One of the Laboratory’s strengths lies in the very tight interaction between researchers, the Haematology cell therapy unit (UTCH) and the clinicians responsible for innovative clinical protocols. The Laboratory brings together a range of skills that make it possible to run projects taking different approaches: cellular and molecular biology, immunology, genomics and next generation sequencing (NGS) and cell therapy. 

The Experimental Haematology Laboratory is essentially active in three key areas:

  • the immune microenvironment in acute leukaemia
  • carcinogenesis induced by the oncoretroviruses HTLV-1 and BLV
  • immunosenescence in patients suffering from lymphoma and chronic lymphoid leukaemia.

Our research has some very important spin-off effects, not only in improving our understanding of the immune system but also in defeating leukaemia and developing clinical decision tools. The new therapeutic approaches based on the immune system promise to be less toxic and more effective in the long term.

Research projects

Project 1

Epigenetic regulation of the immune microenvironment in acute leukaemia - FOCUS ON T REGULATORY LYMPHOCYTES AND MICROARNS

Project 2

STUDY OF THE ANTICANCER, EPIGENETIC AND IMMUNOMODULATING EFFECT OF BIOACTIVE MOLECULES IN THE CASE OF LEUKEMIA AND LYMPHOMA  

Project 3

Deciphering noncoding transcript dependent oncogenic mechanisms and identifying novel cancer drivers in HTLV-1/BLV models of leukemia
  • Project leader : Anne Van Den Broeke
  • Collaborations : 
    • Michel Georges : GIGA Medical Genomics, Unit of Animal Genomics, Université de Liège, Belgium
    • Philip Griebel : Vaccine and Infectious Disease Organization (VIDO/Intervac), University of Saskatchewan, Saskatoon, Canada
    • Genoveffa Franchini : NCI/NIH Bethesda, USA
    Funding : Les Amis de l'Institut Bordet, FNRS, Televie, WALInnov, Fondation Lambeau Marteau

Project 4

Monitoring therapeutic response in ATL and predicting carriers’ risk of progression using optimized NGS clonality methods
  • Project leader : Anne Van Den Broeke
  • Collaborations :
    • Michel Georges : GIGA Medical Genomics, Unit of Animal Genomics, Université de Liège, Belgium
    • Olivier Hermine : Hôpital Necker Enfants Malades and Institut Imagine, Paris, France
    • Toshiki Watanabe and Kaoro Uchimaru : Laboratory of Tumor Cell Biology and JSPFAD, University of Tokyo, Tokyo, Japan
  • Funding : Les Amis de l'Institut Bordet, Televie

Projet 5

Uncovering the key drivers that shape tumor evolution and oncogenic switch: single-cell precision over bulk in viral models of cancer
  • Project leader : Anne Van Den Broeke
  • Collaborations :
    • Michel Georges : GIGA Medical Genomics, Unit of Animal Genomics, Université de Liège, Belgium
    • Thierry Voet : KU Leuven, Belgium and Sanger Institute, UK
    • Philip Griebel : Vaccine and Infectious Disease Organization (VIDO/Intervac), University of Saskatchewan, Saskatoon, Canada
  • Funding : TelevieLes Amis de l'Institut Bordet, International Brachet Stiftung (IBS)

Project 6

Immunosenescence in patients suffering from lymphoma and chronic lymphoid leukaemia: down-regulation of BACH2 in lymphocyte sub-types according to age and correlation with the tumour suppressor gene (TP53 & INK16a)
  • Project leader : Dominique Bron
  • Collaboration : Prof Tamas Fulop (Université de Sherbrooke)
  • Funding : Fondation Yvonne Boël

Our team

Laboratory Director
Philippe Lewalle

Researchers
Makram  Merimi
Snehal Karpe
Anne Van Den Broeke

Hugues Duvillier

PhD students:
Redouane Rouas

Vincent Hahaut
Khalid Ottmani
Douäa Moussa Agha

Bouhtit Fatima (cotutelle, université d’Oujda)
Naima Boushabati (cotutelle, université d’Oujda)

Administrative Assistance
Catherine Primo

13/01/2020

 Scientific publications

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT.

Authors : Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, ODonnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, Baron F, Ciceri F, Esteve J, Gorin NC, Spyridonidis A, Schmid C, Ciurea SO, Nagler A, Mohty M
Year : 2020
Journal : Haematologica
Volume : 105
Pages : 47-58

ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.

Authors : Roy DC, Walker I, Maertens J, Lewalle P, Olavarria E, Selleslag D, Lachance S, Buyse M, Wang K, Rovers J, Santi I, Bonig H, Sandler A, Velthuis J, Mielke S
Year : 2020
Journal : Leukemia

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.

Authors : Roex G, Feys T, Beguin Y, Kerre T, Poiré X, Lewalle P, Vandenberghe P, Bron D, Anguille S
Year : 2020
Journal : Pharmaceutics
Volume : 12

The Impact of Cell-Expansion and Inflammation on The Immune-Biology of Human Adipose Tissue-Derived Mesenchymal Stromal Cells.

Authors : Buyl K, Merimi M, Rodrigues RM, Agha DM, Melki R, Vanhaecke T, Bron D, Lewalle P, Meuleman N, Fahmi H, Rogiers V, Lagneaux L, Kock J, Najar M
Year : 2020
Journal : J Clin Med
Volume : 9

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors : Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2019
Journal : JCI Insight
Volume : 5